Cullinan Therapeutics, Inc. (CGEM) stock
CGEMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 7/30
$8.89−0.18 (-1.98%)
Close on Nov 20, 2026Market cap $572.11MP/E –Yield –
Cullinan Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Cullinan Therapeutics's free cash flow for the twelve months ending Dec 31, 2025 was -$175.80M. For fiscal 2025 it was -$175.80M. The highest annual figure on record is -$29.78M in fiscal 2020.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$175.80M | – |
| FY2024 | Dec 31, 2024 | -$145.30M | – |
| FY2023 | Dec 31, 2023 | -$134.48M | – |
| FY2022 | Dec 31, 2022 | -$127.80M | – |
| FY2021 | Dec 31, 2021 | -$43.43M | – |
| FY2020 | Dec 31, 2020 | -$29.78M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$38.12M | – |
| Q4 FY2024 | Dec 31, 2024 | -$36.63M | – |
| Q3 FY2024 | Sep 30, 2024 | -$34.14M | – |
| Q2 FY2024 | Jun 30, 2024 | -$36.29M | – |
| Q1 FY2024 | Mar 31, 2024 | -$38.25M | – |
| Q4 FY2023 | Dec 31, 2023 | -$18.13M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.14M | – |
| Q2 FY2023 | Jun 30, 2023 | -$31.06M | – |
| Q1 FY2023 | Mar 31, 2023 | -$51.16M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.87M | – |
| Q3 FY2022 | Sep 30, 2022 | -$54.60M | – |
| Q2 FY2022 | Jun 30, 2022 | -$25.42M | – |
| Q1 FY2022 | Mar 31, 2022 | -$21.91M | – |
| Q4 FY2021 | Dec 31, 2021 | -$15.17M | – |
| Q4 FY2020 | Dec 31, 2020 | -$9.44M | – |
| Q3 FY2020 | Sep 30, 2020 | -$9.08M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.25M | – |
| Q1 FY2020 | Mar 31, 2020 | -$5.02M | – |
See a number that looks wrong?